Risiken der homologen Bluttransfusion

  • B. Kubanek
Part of the Klinische Anästhesiologie und Intensivtherapie book series (KAI, volume 43)

Zusammenfassung

Die homologe Bluttransfusion ist, wie die meisten effektiven Therapiemodalitäten, nicht ohne Risiko.Zur Nutzen-Risiko-Abwägung müssen ihre negativen Früh- und Spätfolgen so exakt wie möglich definiert werden.Kenntnisse ihrer Risiken sind darüber hinaus notwendig, um mit und für den Patienten die beste therapeutische Entscheidung zu treffen, und nicht zuletzt, um ihn über mögliche Risiken der homologen Transfusion sowie über bestehende alternative Konzepte der fremdblutsparenden Methoden so objektiv wie möglich aufzuklären.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aach RD, Smzuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, Edwards VM, Wereh J (1981) Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients.The transfusion-transmitted viruses study.N Engl J Med 304: 989–994PubMedCrossRefGoogle Scholar
  2. 2.
    Alter HJ (1989) Discovery of the non-A, non-B hepatitis virus: The end of the beginning or the beginning of the end.Transfusion Med Rev III: 77–81CrossRefGoogle Scholar
  3. 3.
    Alter MJ (1989) Non-A, non-B hepatitis: Sorting through a diagnosis of exclusion.Ann Intern Med 110: 583–585PubMedGoogle Scholar
  4. 4.
    Alter MJ, Coleman PJ, Alexander J, Kramer E, Miller JK, Mandel E, Hadler SC, Margolis HS (1989) Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis.JAMA 262: 1201–1205PubMedCrossRefGoogle Scholar
  5. 5.
    Blumberg N, Heal JM (1989) Transfusion and recipient immune function.Arch Pathol Lab Med 113: 246–253PubMedGoogle Scholar
  6. 6.
    Blumberg N, Ross K, Avila E, Peck K (1984) Should chronic transfusions be matched for antigens other than ABO and Rh0(D)? Vox Sang 47: 205–208PubMedCrossRefGoogle Scholar
  7. 7.
    Blumberg N,Triulzi DJ, Heal JM (1990) Transfusion-induced immunomodulation and its clinical consequences.Transfusion Med Rev [Suppl 1] IV: 24–35CrossRefGoogle Scholar
  8. 8.
    Brantley SG, Ramsey G (1988) Red cell alloimmunization in multitransfused HLA-typed patients.Transfusion 28: 463–466PubMedCrossRefGoogle Scholar
  9. 9.
    Cuthbert JA (1989) Report from Grand Rounds.University of Texas, SW Med CenterGoogle Scholar
  10. 10.
    Dienstag J (1983) Non-A, non-B hepatitis.I.Recognition, epidemiology, and clinical features.Gastroenterology 85: 439–462PubMedGoogle Scholar
  11. 11.
    Dodd RY (1989) Screening for hepatitis infectivity among blood donors.A model for blood safety? Arch Pathol Lab Med 113: 227–231PubMedGoogle Scholar
  12. 12.
    Frankish PD, McNee RK, Alley PG et al. (1985) Relation between cancer of the colon and blood transfusion (letter).Br Med J 291: 554CrossRefGoogle Scholar
  13. 13.
    Glück D, Gaus W, Wieland C, Kubanek B (1988) Transfusions-Hepatitis.Häufigkeit und Risikovergleich zwischen Bluttransfusion und Operation.Dtsch Med Wochenschr 113: 1463–1468PubMedCrossRefGoogle Scholar
  14. 14.
    Glück D, Vornwald A, Gossrau E, Kubanek B (1990) HIV prevalence in blood donors in urban and in rural areas of the Federal Republic Germany.Blut 60: 304–307PubMedCrossRefGoogle Scholar
  15. 15.
    Hermanek P jr, Guggenmoos-Holzmann I, Schricker KT, Resch T, Freudenberger K, Neidhardt P, Gall FP (1989) Der Einfluß der Transfusion von Blut und Haemoderivaten auf die Prognose des colorektalen Carcinoms.Langenbecks Arch Chir 374: 118–124PubMedCrossRefGoogle Scholar
  16. 16.
    Koerner K, Stampe D, Glück D, Kubanek B (in Vorbereitung) Antibodies to hepatitis C and surrogate markers in blood donors.Vox SangGoogle Scholar
  17. 17.
    Opelz G,Terasaki PI (1974) Poor kidney-transplant survival in recipients with frozen blood transfusions or no transfusions.Lancet II: 696–698CrossRefGoogle Scholar
  18. 18.
    Reesink HW,Van der Poel CL (1989) Blood transfusion and hepatitis: still a threat? Blut 58: 1–6PubMedCrossRefGoogle Scholar
  19. 19.
    Sazama K (1990) Reports of 355 transfusion-associated deaths: 1976 through 1985.Transfusion 30: 583–590PubMedCrossRefGoogle Scholar
  20. 20.
    Tremolada F, Casarin C, Tagger A, Ribero ML, Realdi G, Albert A, Ruol A (1991) Antibody to hepatitis C virus in post-transfusion hepatitis.Ann Intern Med 114: 277–281PubMedGoogle Scholar
  21. 21.
    Van Aken WG (1989) Does perioperative blood transfusion promote tumor growth? Transfusion Med Rev III: 243–252CrossRefGoogle Scholar
  22. 22.
    Van der Poel CL, Reesink HW, Lelie PN, Leentvaar-Kuypers A, Choo Q-L, Kuo G, Houghton M (1989) Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands.Lancet II: 297–298Google Scholar
  23. 23.
    Walker RH, Lin D-T, Hartrick MB (1989) Alloimmunization following blood transfusion.Arch Pathol Lab Med 113: 254–261PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • B. Kubanek

There are no affiliations available

Personalised recommendations